Post-earnings recap
Reported
Thu, May 11, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Madrigal Pharmaceuticals reported a loss per share of $0.50, but did not provide revenue figures. The stock rose by 2.57% following the earnings release, indicating some investor optimism despite the lack of detailed financial metrics. The management's focus on clinical programs may have contributed to the positive stock reaction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.50 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a commitment to their clinical programs and strategic objectives. They highlighted the importance of ongoing development efforts.
We are focused on advancing our clinical programs.
Our team remains dedicated to achieving our strategic goals.